Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
|Articles|September 4, 2013
Michael Maves Appointed Senior VP of Development at USP
The surgeon and former USP trustee hails from ProjectHOPE.
Advertisement
The U.S. Pharmacopeial Convention (USP; Rockville, MD) has installed Michael D. Maves, M.D., M.B.A., F.A.C.S., into the newly-created position of senior vice president of development, where he will oversee “capacity-building activities in resource-constrained parts of the world,” according to USP CEO. Roger Williams.
A board-certified surgeon, Dr. Maves previously served on USP’s Board of Trustees and was most recently the executive vice president of the global nonprofit health education and humanitarian assistance organization, Project HOPE. He also previously held the title of executive vice president and CEO of the American Medical Association.
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
2
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
3
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
4
Thirty Years of GCP: The Evolution From Study Execution to Evidence Generation
5